CoChat

Pegylated asparaginase (OncasparTM) in children with ALL: drug monitoring in reinduction according to the ALL/NHL‐BFM 95 protocols

Open access
Müller, Hans‐Joachim, Löning, Lutz, Horn, Alexander, Schwabe, Dirk, Gunkel, Martin, Schrappe, Martin, Von Schütz, Volker, Henze, Günter, Casimiro da Palma, João, Ritter, Jörg, Pinheiro, João Paulo Vieira, Winkelhorst, Monika, Boos, Joachim · 2000 · British Journal of Haematology
Cited by 120

The DOI matches its Crossref record.

Abstract

Hypersensitivity reactions are relevant adverse effects of asparaginase therapy. Therefore, children treated with native Escherichia coli asparaginase in induction therapy of acute lymphoblastic leukaemia (ALL) or non‐Hodgkin's lymphoma (NHL) were switched to the pegylated enzyme for reinduction under drug monitoring. Seventy children, including four patients with allergic reactions during induction, were given one dose of Oncaspar TM 1000 U/m 2 intravenously. Activity was determined every third or fourth day until it dropped below the limit of quantification. In current reinduction protocols [ALL/NHL‐Berlin–Frankfurt–Münster (BFM) 95 trials], four doses of 10 000 U/m 2E. coli asparaginase deplete asparagine for about 2–3 weeks, therefore activities of ≥ 100 U/l up to day 14 and ≥ 50 U/l up to day 21 were targeted. In 66 patients without an allergic reaction during induction, the mean activity was 606 ± 313 U/l, 232 ± 211 U/l and 44 ± 50 U/l after 1, 2 and 3 weeks respectively. In 44/66 patients, activity was ≥ 100 U/l after 14 d. A rapid decline in activity was seen in the remaining 22 patients, including 8/22 patients who showed no activity after 1 week. Toxicity was low and comparable to the native enzymes but, in contrast to about 30% of hypersensitivity reactions with conventional reinduction therapy, no allergic reaction was seen. Substituting 4 × 10 000 U/m 2 asparaginase medac for one dose of 1000 U/m 2 Oncaspar TM was safe and well tolerated. Comparable pharmacokinetic treatment intensity was achieved in about two‐thirds of patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2141.2000.02187.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 120

Metadata

Authors
Müller, H., Löning, L., Horn, A., Schwabe, D., Gunkel, M., Schrappe, M., Von Schütz, V., Henze, G., Casimiro da Palma, J., Ritter, J., Pinheiro, J. P. V., Winkelhorst, M., & Boos, J.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2000-08
Volume
110
Issue
2
Pages
379-384
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2047657755
Cited by
120
References
0
FWCI
6.76
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pegylated asparaginase (OncasparTM) in children with ALL: drug monitoring in reinduction according to the ALL/NHL‐BFM 95 protocols. https://app.cochat.ai/papers/10.1046/j.1365-2141.2000.02187.x
The paper
Müller, H., Löning, L., Horn, A., Schwabe, D., Gunkel, M., Schrappe, M., Von Schütz, V., Henze, G., Casimiro da Palma, J., Ritter, J., Pinheiro, J. P. V., Winkelhorst, M., & Boos, J. (2000). Pegylated asparaginase (OncasparTM) in children with ALL: drug monitoring in reinduction according to the ALL/NHL‐BFM 95 protocols. British Journal of Haematology. https://doi.org/10.1046/j.1365-2141.2000.02187.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.